Stock Ratings / Health Care / ONCO / options

ERNA (46) GRI (38) CVKD (40) EOCN (47) ⌘ Pro Terminal →

Onconetix Inc. (ONCO) Options Positioning, Max Pain & Unusual Sweeps

$0.59 -1.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Onconetix Inc. (ONCO) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D- • RED ALERT Cap $3.5M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERRED ALERT • D-

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-10.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ONCO)Realized 20D OHLCV Swing Band: ±12.5%

CALL VS. PUT WHALE SHARE

— (No Active Options Snapshot)

Put/Call Ratio: — (No Active Options Snapshot)

MAX-PAIN EXPIRATION MAGNET

— (No Active Options Snapshot)

No active options chain max-pain snapshot on file

HISTORICAL 20D VOLATILITY SWING

±12.5%

Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ONCO)

— (No Active Options Snapshot) — No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ONCO.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

🏆 Enter Free $100K Paper Arena →

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ONCO)

✓Walkthrough of ONCO's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ONCO // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -91.51%🛡️ HOLDING TREND SUPPORT

2026-10-30O $0.54H $0.59L $0.52C $0.59VOL 1.17M

RES: $1.52SUP: $0.32SMA50: $0.66SMA200: $13.89

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ONCO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ONCO Butterfly Map → + Track ONCO →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ONCO today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ONCO. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ONCO today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ONCO)

Health Care Rank #803 of 1016 ⚔️ ERNA vs ONCO Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ONCO vs. ERNA, GRI, CVKD, EOCN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Onconetix Inc. (ONCO) ranks #803 by composite RQD confidence (36/100, grade D-) and #971 by equity capitalization ($3.5M). Within this direct 5-issuer industry benchmark cohort, ONCO leads on earnings valuation at N/A trailing P/E, while ONCO leads on capital efficiency and profitability with -35.0% ROIC and 77.6% gross margin. EOCN currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with ONCO at 36/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ONCO ACTIVE Onconetix Inc.	D-	36/100	—	77.6%	-35.0%	-1.99%	$3.5M	Benchmark Subject
ERNA Ernexa Therapeutics Inc.	D	46/100	—	—	-35.0%	+6.57%	$3.4M	/erna-vs-onco →
GRI GRI Bio Inc.	D-	38/100	—	—	-35.0%	-3.38%	$3.4M	/gri-vs-onco →
CVKD Cadrenal Therapeutics Inc.	D-	40/100	—	—	-35.0%	-0.47%	$3.4M	/cvkd-vs-onco →
EOCN Eocene Ltd.	D	47/100	—	—	-35.0%	+0.62%	$3.4M	/eocn-vs-onco →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001782107

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Onconetix Inc. (ONCO) reported GAAP revenue of $815.4K (-67.7% vs. FY2024 revenue of $2.5M , and +1294.6% cumulative change since FY2023) , GAAP net income of -$14.0M, operating cash flow of -$9.7M, and free cash flow of -$9.7M (+8.0% YoY). On the balance sheet, ONCO closed FY2025 with $24.9M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$815.4K	-$14.0M	-$9.7M	-$9.7M	$24.9M	—
FY2024 (FY)	2024-12-31	$2.5M	-$58.7M	-$10.5M	-$10.5M	$28.2M	—
FY2023 (FY)	2023-12-31	$58.5K	-$37.4M	-$13.6M	-$13.6M	—	—

3. ONCO Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ONCO stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Onconetix Inc. (NASDAQ: ONCO) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $0.59 (-1.99% 1D, market cap $3.5M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ONCO ranks #803 in composite RQD confidence.

How does ONCO compare to ERNA and GRI in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ONCO carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of 77.6%, and ROIC of -35.0%. By comparison, ERNA (Ernexa Therapeutics Inc.) holds a D grade (46/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M) and GRI (GRI Bio Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $3.4M). Among the 5-stock peer group, ONCO leads on earnings multiple (N/A) while ONCO leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ONCO?

Per ONCO's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001782107), Onconetix Inc. generated $815.4K in revenue (-67.7% YoY), -$14.0M in net income, and -$9.7M in free cash flow against $24.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ONCO trading relative to its 50-day, 200-day, and 52-week technical levels?

ONCO last traded at $0.59 (-1.99% on volume of 6,910,992 shares), positioning the stock -10.61% below its 50-day simple moving average ($0.66) and -95.75% below its 200-day simple moving average ($13.89). Across its 52-week range of $0.34 to $166.25, ONCO sits at the 0.2% percentile with a 14-day RSI of 48.3 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.66).

ONCO Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is ONCO's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ONCO.

Direct Sub-Reports: ONCO RQD Cockpit ONCO 12M Forecast ONCO Earnings & Move ONCO Dividends & DRIP ONCO Insiders & 13F ONCO Whale Options ONCO Profit Sankey ONCO News & Why